KAKenta Aso

Kenta Aso

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kenta Aso has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply to Ben Ismail et al.

    by Kenta Aso, Yoshinori Takeda, Akio Saiura

  • Biologically Refined Oncological Resectability for Hepatocellular Carcinoma

    by Kenta Aso, Yoshinori Takeda, Atsushi Takahashi, Shoichi Irie, Yoshihiro Hirata, Hirofumi Ichida, Ryuji Yoshioka, Yoshihito Kotera, Yoshihiro Mise, Akio Saiura

    Background/Purpose: Oncological resectability criteria for hepatocellular carcinoma (HCC) have been proposed to guide multidisciplinary treatment, but their validation remains limited. Incorporating biological factors may improve prognostic stratification and identification of borderline‐resectable HCC. Methods: Patients undergoing initial hepatectomy for HCC (2009–2022) were classified as resectable (R), borderline‐resectable (BR)1, or BR2. Stratification of overall survival (OS) and recurrence‐free survival (RFS) was compared with the BCLC staging system. R‐group patients with alpha‐fetoprotein (AFP) ≥ 400 ng/mL and des‐gamma‐carboxy prothrombin (DCP) ≥ 400 mAU/mL were subclassified as biological‐BR. Results: Among 391 patients (R: 330; BR1: 23; BR2: 38), survival stratification was comparable to the BCLC classification. Twenty‐six R‐group patients were reclassified as biological‐BR, with higher microvascular invasion rates (42.3%) and 5 year OS and 3 year RFS similar to BR1 patients (54.9% vs. 51.3%, p = 0.457; 38.1% vs. 25.0%, p = 0.954). Combining Biological BR with BR1 significantly improved time‐dependent prediction of 6 month recurrence, with an area under the receiver operating characteristic curve (Refined: 0.803; Original: 0.658, p ≤ 0.001, BCLC: 0.608, p ≤ 0.001) and net reclassification improvement (0.220 vs. Original; 0.446 vs. BCLC). Conclusions: Refinement using AFP and DCP identified a biologically aggressive subset within the R group and may improve early recurrence prediction.


  • Open Access

    Pancreatic Head Cancer Masquerading as Distal Cholangiocarcinoma: Diagnostic Challenges, Tumor Characteristics, and Oncologic Outcomes

    by Kenta Aso, Ryuji Yoshioka, Atsushi Takahashi, Shoichi Irie, Yoshinori Takeda, Yoshihiro Hirata, Takaaki Kato, Hirofumi Ichida, Yoshihito Kotera, Yoshihiro Mise, et al.

    Background/Objectives: Differentiating pancreatic head cancer (PHC) from distal cholangiocarcinoma (dCCA) remains clinically challenging and directly influences treatment strategy. This study evaluates the clinicopathologic features and outcomes of patients with PHC who were preoperatively designated as dCCA. Methods: We retrospectively analyzed patients undergoing pancreatoduodenectomy for suspected dCCA or PHC from 2019 to 2023. Patients were stratified by pre- and postoperative diagnoses into three groups: confirmed dCCA (B-B), confirmed PHC (P-P), and dCCA reclassified as PHC (B-P). Clinicopathologic features, perioperative outcomes, and survival were compared. Results: This analysis included 159 patients, B-B = 31, P-P = 115, and B-P = 13. Despite a more advanced stage, a lower R0 rate (p = 0.043), and unplanned portal vein resection confined to B-P (p < 0.001), overall and recurrence-free survival were comparable to P-P (p = 0.363 and 0.183). In multivariable Cox analysis, B-P remained an independent favorable prognostic factor for overall survival (Hazard ratio 0.137, p = 0.020). Conclusions: Approximately one-third of cases initially diagnosed as dCCA were ultimately PHC. These PHC cases mimicking dCCA demonstrated comparable or even superior survival, suggesting a biologically indolent subset. Refinement of diagnostic criteria and integrated clinicopathologic assessment are essential for optimizing preoperative management strategies.

  • Open Access

    Curative Surgery for Malignant Sigmoid–Duodenal Fistula Caused by Colon Cancer: A Case Report

    by Saho Aso, Moe Tasaki, Kenta Aso, Yuzuru Ito, Shunsuke Shirakawa, Kentaro Kawamitsu, Takuji Noro, Michio Machida, Hiroyuki Sugo

    INTRODUCTION: A malignant sigmoid colon–duodenal fistula is extremely rare, and optimal management strategies remain unclear.CASE PRESENTATION: A 66-year-old man was admitted to a local hospital with melena. Lower gastrointestinal endoscopy identified a circumferential type 3 tumor located in the sigmoid colon. Upper gastrointestinal endoscopy revealed extrinsic tumor invasion into the horizontal portion of the duodenum. Contrast-enhanced abdominal CT demonstrated irregular thickening of the sigmoid colon wall, which appeared to be contiguous with the horizontal portion of the duodenum, with evidence of luminal continuity. Based on a diagnosis of malignant sigmoid–duodenal fistula, the patient underwent open surgery. At laparotomy, the sigmoid colon cancer was found to be directly invading the duodenojejunal flexure, arising from the ligament of Treitz on the left side of the superior mesenteric artery, which made preservation of the duodenum difficult. Therefore, Hartmann’s procedure with concomitant segmental duodenectomy was performed while preserving the pancreas. For duodenal reconstruction, a Roux-en-Y jejunal limb was created and anastomosed to the second portion of the duodenum. Additionally, a gastrojejunostomy in the Billroth II configuration was performed.CONCLUSIONS: Malignant invasion of the duodenum is often associated with involvement of major vessels or the need for pancreatic resection, which may render curative resection difficult or excessively invasive. However, segmental duodenectomy with preservation of the pancreas can be a valuable surgical option in selected cases.